Key result
Sequential chemotherapy starting with paclitaxel resulted in a prolonged overall survival of 14.2 months in a patient with unresectable pulmonary artery intimal sarcoma.
Why the study?
Pulmonary artery intimal sarcoma is rare, leaving little known about efficacious systemic chemotherapies when tumors are unresectable or metastatic.
Case Report (n=1)
No
Sequential chemotherapy including paclitaxel may provide prolonged survival in patients with unresectable pulmonary artery intimal sarcoma.
Answers are grounded in this paper and cite their sources.
May support paclitaxel-based sequential chemotherapy in unresectable pulmonary artery intimal sarcoma; hypothesis-generating from single case report.
Pulmonary artery intimal sarcoma is a rare malignant tumor. Due to its low prevalence, little is known about efficacious systemic chemotherapies in cases where the tumors are unresectable or metastatic. In addition, the location of the disease can contribute to poor survival regardless of the response to therapy, as the tumor's position can cause pulmonary artery hypertension either rapidly or chronically. We encountered a case of unresectable pulmonary artery intimal sarcoma with lung metastases. Treatment with several cytotoxic agents resulted in prolonged survival of 14.2 months. Here, we report the clinical course of this case and present a review of the relevant literature.
No takes yet. Share an insight, caveat, or question.
Noguchi et al. (2019) conducted a case report in Unresectable pulmonary artery intimal sarcoma (n=1). Sequential chemotherapy (paclitaxel, doxorubicin, gemcitabine, eribulin) was evaluated on Overall survival. Sequential chemotherapy starting with paclitaxel resulted in a prolonged overall survival of 14.2 months in a patient with unresectable pulmonary artery intimal sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: